Keywords: Diabetic nephropathy, renal disease, hypertension, blood pressure, antihypertensive treatment, ACE-1, ARB, dual blockade.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mogensen, CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand. J. Clin. Lab. Invest. 36:383–388, 1976.
Mogensen, CE: Diabetic renal disease: the quest for normotension–and beyond. Diabet. Med. 12:756–769, 1995.
Hasslacher, C, Stech, W, Wahl, P, Ritz, E: Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 28:6–11, 1985.
Berglund, J, Lins, LE, Lins, PE: Metabolic and blood pressure monitoring in diabetic renal failure. Acta Med. Scand. 218:401–408, 1985.
Parving, H-H, Hommel, E, Mathiesen, E, Skott, P, Edsberg, B, Bahnsen, M, Lauritzen, M, Hougaard, P, Lauritzen, E: Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br. Med. J. (Clin. Res. Ed.) 296:156–160, 1988.
Rossing, P, Hommel, E, Smidt, UM, Parving, H-H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715–719, 1993.
Hovind, P, Rossing, P, Tarnow, L, Smidt, UM, Parving, H-H: Progression of diabetic nephropathy. Kidney Int. 59:702–709, 2001.
Mogensen, CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br. Med. J. (Clin. Res. Ed.) 285:685–688, 1982.
Parving, HH, Andersen, AR, Smidt, UM, Svendsen, PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175–1179, 1983.
Anderson, S, Brenner, BM: Influence of antihypertensive therapy on development and progression of diabetic glomerulopathy. Diabetes Care 11:846–849, 1988.
Parving, H-H, Smidt, UM, Hommel, E, Mathiesen, ER, Rossing, P, Nielsen, F, Gall, MA: Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am. J. Kidney Dis. 22:188–195, 1993.
Parving, HH, Hommel, E: Prognosis in diabetic nephropathy [see comments]. BMJ 299:230–233, 1989.
Mathiesen, ER, Borch Johnsen, K, Jensen, DV, Deckert, T: Improved survival in patients with diabetic nephropathy. Diabetologia 32:884–886, 1989.
Hasslacher, C, Borgholte, G, Ritz, E, Wahl, P: Impact of hypertension on prognosis in IDDM. Diabete Metab. 15:338–342, 1989.
Astrup, AS, Tarnow, L, Rossing, P, Pietraszek, L, Riis, HP, Parving, HH: Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int. 68:1250–1257, 2005.
Adler, AI, Stratton, IM, Neil, HA, Yudkin, JS, Matthews, DR, Cull, CA, Wright, AD, Turner, RC, Holman, RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419, 2000.
Haffner, SM, Lehto, S, Ronnemaa, T, Pyorala, K, Laakso, M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:229–234, 1998.
Juutilainen, A, Lehto, S, Ronnemaa, T, Pyorala, K, Laakso, M: Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28:2901–2907, 2005.
Booth, GL, Kapral, MK, Fung, K, Tu, JV: Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29–36, 2006.
Chobanian, AV, Bakris, GL, Black, HR, Cushman, WC, Green, LA, Izzo, JL, Jr., Jones, DW, Materson, BJ, Oparil, S, Wright, JT, Jr., Roccella, EJ: The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572, 2003.
Berl, T, Hunsicker, LG, Lewis, JB, Pfeffer, MA, Porush, JG, Rouleau, JL, Drury, PL, Esmatjes, E, Hricik, D, Pohl, M, Raz, I, Vanhille, P, Wiegmann, TB, Wolfe, BM, Locatelli, F, Goldhaber, SZ, Lewis, EJ: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J. Am. Soc. Nephrol. 16:2170–2179, 2005.
Cruickshank, JM: Antihypertensive treatment and the J-curve. Cardiovasc. Drugs Ther. 14:373–379, 2000.
Hansson, L: Antihypertensive treatment: does the J-curve exist? Cardiovasc. Drugs Ther. 14:367–372, 2000.
Hansson, L, Zanchetti, A, Carruthers, SG, Dahlof, B, Elmfeldt, D, Julius, S, Menard, J, Rahn, KH, Wedel, H, Westerling, S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments]. Lancet 351:1755–1762, 1998.
Williams, B, Poulter, NR, Brown, MJ, Davis, M, McInnes, GT, Potter, JF, Sever, PS, McG, TS: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J. Hum. Hypertens. 18:139–185, 2004.
American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 28 Suppl 1:S4–S36, 2005.
Rahman, M, Pressel, S, Davis, BR, Nwachuku, C, Wright, JT, Jr., Whelton, PK, Barzilay, J, Batuman, V, Eckfeldt, JH, Farber, M, Henriquez, M, Kopyt, N, Louis, GT, Saklayen, M, Stanford, C, Walworth, C, Ward, H, Wiegmann, T: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 165:936–946, 2005.
Levey, AS, Uhlig, K: Which antihypertensive agents in chronic kidney disease? Ann. Intern. Med. 144:213–215, 2006.
Hollenberg, NK: Omission of drug dose information. Arch. Intern. Med. 166:368–369, 2006.
Casas, JP, Chua, W, Loukogeorgakis, S, Vallance, P, Smeeth, L, Hingorani, AD, MacAllister, RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033, 2005.
Rossing, P, Parving, HH, de Zeeuw, D: Renoprotection by blocking the RAAS in diabetic nephropathy–fact or fiction? Nephrol. Dial. Transplant. 21:2354–2357, 2006.
Hovind, P, Rossing, P, Tarnow, L, Toft, H, Parving, J, Parving, HH: Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24:1972–1977, 2001.
Hovind, P, Tarnow, L, Rossing, P, Carstensen, B, Parving, HH: Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 66:1180–1186, 2004.
Ibsen, H, Olsen, MH, Wachtell, K, Borch-Johnsen, K, Lindholm, LH, Mogensen, CE, Dahlof, B, Snapinn, SM, Wan, Y, Lyle, PA: Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 29:595–600, 2006.
de Zeeuw, D, Remuzzi, G, Parving, HH, Keane, WF, Zhang, Z, Shahinfar, S, Snapinn, S, Cooper, ME, Mitch, WE, Brenner, BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921–927, 2004.
Suissa, S, Hutchinson, T, Brophy, JM, Kezouh, A: ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 69:913–919, 2006.
Lewis, EJ, Hunsicker, LG, Clarke, WR, Berl, T, Pohl, MA, Lewis, JB, Ritz, E, Atkins, RC, Rohde, R, Raz, I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 20;345:851–860, 2001.
Lewis, EJ, Hunsicker, LG, Bain, RP, Rohde, RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [see comments] [published erratum appears in N. Engl. J. Med. Jan 13;330(2):152, 1993]. N. Engl. J. Med. 329:1456–1462, 1993.
The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive Angiotensin-Converting Enzyme Inhibitors? A meta-analysis of individual patient data. Ann. Intern. Med. 134:340–379, 2001.
Mogensen, CE, Keane, WF, Bennett, PH, Jerums, G, Parving, HH, Passa, P, Steffes, MW, Striker, GE, Viberti, GC: Prevention of diabetic renal disease with special reference to microalbuminuria [see comments]. Lancet 346:1080–1084, 1995.
Cooper, ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352:213–219, 1998.
Ruggenenti, P, Fassi, A, Ilieva, AP, Bruno, S, Iliev, IP, Brusegan, V, Rubis, N, Gherardi, G, Arnoldi, F, Ganeva, M, Ene-Iordache, B, Gaspari, F, Perna, A, Bossi, A, Trevisan, R, Dodesini, AR, Remuzzi, G: Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351:1941–1951, 2004.
Parving, HH, Lehnert, H, Brochner-Mortensen, J, Gomis, R, Andersen, S, Arner, P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 20;345:870–878, 2001.
Brenner, BM, Cooper, ME, de Zeeuw, D, Keane, WF, Mitch, WE, Parving, HH, Remuzzi, G, Snapinn, SM, Zhang, Z, Shahinfar, S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 20;345:861–869, 2001.
Parving, HH, Hovind, P, Rossing, P: Telmisartan vs. enalapril in type 2 diabetes. N. Engl. J. Med. 352:835–836, 2005.
Lacourciere, Y, Belanger, A, Godin, C, Halle, JP, Ross, S, Wright, N, Marion, J: Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 58:762–769, 2000.
Shoda, J, Kanno, Y, Suzuki, H: A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern. Med. 45:193–198, 2006.
Nichols, GA, Gullion, CM, Koro, CE, Ephross, SA, Brown, JB: The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884, 2004.
Verma, S, Strauss, M: Angiotensin receptor blockers and myocardial infarction. BMJ 329:1248–1249, 2004.
Strippoli, GF, Craig, M, Deeks, JJ, Schena, FP, Craig, JC: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329:828, 2004.
Ihara, M, Urata, H, Kinoshita, A, Suzumiya, J, Sasaguri, M, Kikuchi, M, Ideishi, M, Arakawa, K: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33:1399–1405, 1999.
Savoia, C, Touyz, RM, Endemann, DH, Pu, Q, Ko, EA, De Ciuceis, C, Schiffrin, EL: Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 48:271–277, 2006.
Andersen, NH, Poulsen, PL, Knudsen, ST, Poulsen, SH, Eiskjaer, H, Hansen, KW, Helleberg, K, Mogensen, CE: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28:273–277, 2005.
Rossing, K, Schjoedt, KJ, Jensen, BR, Boomsma, F, Parving, HH: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 68:1190–1198, 2005.
Schmieder, RE, Klingbeil, AU, Fleischmann, EH, Veelken, R, Delles, C: Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J. Am. Soc. Nephrol. 16:3038–3045, 2005.
Nakao, N, Kimura, G: Submaximal dose of trandolapril in the COOPERATE trial? Kidney Int. 64:1921–1922, 2003.
Kanno, Y, Takenaka, T, Nakamura, T, and Suzuki, H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin. J. Am. Soc. Nephrol. 1:730–737, 2006.
MacKinnon, M, Shurraw, S, Akbari, A, Knoll, GA, Jaffey, J, Clark, HD: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am. J. Kidney Dis. 48:8–20, 2006.
Rossing, K, Schjoedt, KJ, Smidt, UM, Boomsma, F, Parving, HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28:2106–2112, 2005.
Sato, A, Hayashi, K, Naruse, M, Saruta, T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64–68, 2003.
van den Meiracker, AH, Baggen, RG, Pauli, S, Lindemans, A, Vulto, AG, Poldermans, D, Boomsma, F: Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J. Hypertens. 24:2285–2292, 2006.
Schjoedt, KJ, Rossing, K, Juhl, TR, Boomsma, F, Tarnow, L, Rossing, P, Parving, HH: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70:536–542, 2006.
Rachmani, R, Slavachevsky, I, Amit, M, Levi, Z, Kedar, Y, Berla, M, Ravid, M: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet. Med. 21:471–475, 2004.
van den Meiracker AH, Baggen, RGA, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F: Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J. Hypertens. 24:2285–2292, 2006.
Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1:940–951, 2006.
Danish National Registry Report on Dialysis and Transplantation in Denmark, 2005. www.Nephrology.dk.
U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006.
National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 49;2:S12–S154, 2007.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al.: Definition, evaluation, and classification of renal osteodystrophy:: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69;11:1945–1953, 2006.
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42:1–201, 2003.
National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am. J. Kidney Dis. 47:S1–S146, 2006.
Lameire N, Wauters J-P, Teruel JLG, Bissen WV, Vanholder R. An update on the referral pattern of patients with end-stage renal disease. Kidney Int. 61:S27–S34, 2002.
Hebert, LA, Falkenhain, ME, Nahman, NS, Jr., Cosio, FG, O'Dorisio, TM: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am. J. Nephrol. 19:1–6, 1999.
Rossing, K, Christensen, PK, Jensen, BR, Parving, HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25:95–100, 2002.
Rossing, K, Jacobsen, P, Pietraszek, L, Parving, HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26:2268–2274, 2003.
Jacobsen, P, Andersen, S, Rossing, K, Hansen, BV, Parving, HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol. Dial. Transplant. 17:1019–1024, 2002.
Jacobsen, P, Andersen, S, Rossing, K, Jensen, BR, Parving, HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 63:1874–1880, 2003.
Mogensen, CE, Neldam, S, Tikkanen, I, Oren, S, Viskoper, R, Watts, RW, Cooper, ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440–1444, 2000.
Andersen, NH, Poulsen, PL, Knudsen, ST, Poulsen, SH, Eiskjaer, H, Hansen, KW, Helleberg, K, Mogensen, CE: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28:273–277, 2005.
Sengul, AM, Altuntas, Y, Kurklu, A, Aydin, L: Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res. Clin. Pract. 71:210–219, 2006.
Tutuncu, NB, Gurlek, A, Gedik, O: Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol. 38:157–161, 2001.
Matos, JP, de Lourdes, RM, Ismerim, VL, Boasquevisque, EM, Genelhu, V, Francischetti, EA: Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin. Nephrol. 64:180–189, 2005.
Fujisawa, T, Ikegami, H, Ono, M, Nishino, M, Noso, S, Kawabata, Y, Ogihara, T: Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am. J. Hypertens. 18:13–17, 2005.
Song, JH, Lee, SW, Suh, JH, Kim, ES, Hong, SB, Kim, KA, Kim, MJ: The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin. Nephrol. 60:318–326, 2003.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Poulsen, P.L., Poulsen, J.V. (2007). ACE-I and ARB and Blood Pressure Lowering, Including Effect on Renal Disease. Treatment of Advanced Diabetic Renal Disease. In: Mogensen, C.E. (eds) Pharmacotherapy of Diabetes: New Developments. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-69737-6_18
Download citation
DOI: https://doi.org/10.1007/978-0-387-69737-6_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-69736-9
Online ISBN: 978-0-387-69737-6
eBook Packages: MedicineMedicine (R0)